Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Case Report
Case series
Editorial
Erratum
Guest Editorial
Letter to Editor
Letter to the Editor
Media and News
Medial Education
Medical Education
Obituary
Opinion Article
Original Article
Review Article
Short Communication
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Case Report
Case series
Editorial
Erratum
Guest Editorial
Letter to Editor
Letter to the Editor
Media and News
Medial Education
Medical Education
Obituary
Opinion Article
Original Article
Review Article
Short Communication
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Case Report
Case series
Editorial
Erratum
Guest Editorial
Letter to Editor
Letter to the Editor
Media and News
Medial Education
Medical Education
Obituary
Opinion Article
Original Article
Review Article
Short Communication
View/Download PDF

Translate this page into:

Case Series
70 (
1
); 78-79
doi:
10.25259/IJPP_714_2024

Vivid dreams and oscillopsia associated with propranolol – A report of two cases

Department of Pharmacology, Sree Uthradom Thirunal Academy of Medical Sciences, Thiruvananthapuram, Kerala, India.

*Corresponding author: Asida Mohamed Ashraf, Department of Pharmacology, Sree Uthradom Thirunal Academy of Medical Sciences, Thiruvananthapuram, Kerala, India. drasidaraj@gmail.com

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Ashraf AM, Retnakumar AA. Vivid dreams and oscillopsia associated with propranolol – A report of two cases. Indian J Physiol Pharmacol. 2026;70:78-9. doi: 10.25259/IJPP_714_2024

Abstract

Propranolol, a beta-adrenergic blocker, is commonly used for migraine prophylaxis and other indications. While its side effects include fatigue, dizziness and sleep disturbances, vivid dreams and oscillopsia are rarely reported. This case report describes two instances of vivid dreams and oscillopsia in patients prescribed propranolol for migraine management. The cases highlight the need for heightened awareness of such adverse effects, especially in long-term therapy.

Keywords

Adverse effects
Migraine prophylaxis
Oscillopsia
Propranolol
Vivid dreams

INTRODUCTION

Propranolol is a non-selective beta-adrenergic receptor antagonist widely used in the management of migraines, essential tremors, myocardial infarction, arrhythmia and hypertension. It is said to be almost as effective as third-generation beta-blockers for arrhythmias.[1] The use of propranolol as a first-line drug in the prophylaxis of migraine is very commonplace.[2] Although propranolol is generally well-tolerated and has adverse effects related to sympathetic blockade, such as bradycardia and hypoglycaemic unawareness, central nervous system (CNS) side effects, such as vivid dreams and visual disturbances, are uncommon but clinically significant.[3] This report highlights two cases of vivid dreams and oscillopsia associated with propranolol use, emphasising the importance of recognising and managing these adverse effects and providing alternative therapies.

CASE SERIES

Case 1

A 34-year-old female with a history of chronic migraine and seronegative spondyloarthropathy was prescribed propranolol 40 mg once daily on May 25, 2024, for migraine prophylaxis. Two nights after initiating the medication, the patient experienced vivid dreams. During the daytime, she reported an illusion of moving objects, described as oscillopsia. Despite these symptoms, she continued propranolol due to persistent migraine attacks. She had previously used a combination of propranolol and amitriptyline for migraine management 2 years ago without similar adverse effects. Her medical and surgical history was otherwise insignificant.

Case 2

A 13-year-old female with a known history of seizure disorder and migraine was prescribed propranolol 40 mg twice daily in combination with sodium valproate 500 mg on February 08, 2024. After 1 week of initiating propranolol, the patient began experiencing vivid dreams, occurring at least three times per week. These symptoms persisted until the date of reporting on July 07, 2024. The patient continued the medication despite the adverse effects, given the ongoing management of migraines. She had no significant medical or surgical history other than the diagnosed conditions.

DISCUSSION

Beta-adrenergic blockers like propranolol cross the blood– brain barrier, potentially causing CNS effects such as vivid dreams, sleep disturbances and hallucinations. The vivid dreams reported by both patients could be attributed to the lipophilic nature of propranolol, facilitating its CNS penetration and interaction with sleep-regulating pathways.[4,5]

Oscillopsia, characterised by an illusion of moving objects, is an unusual adverse effect. Some of the causes are meningitis, tumours, Meniere’s disease, drugs, etc. Some drugs that can cause oscillopsia are gabapentin and clonazepam. It may result from the drug’s influence on vestibular function or cortical processing. Interestingly, the first patient experienced oscillopsia within 3 days of starting propranolol, while the second patient did not report visual disturbances, indicating variability in individual susceptibility. Beta-blockers such as propranolol, metoprolol and pindolol can cross the blood-brain barrier due to high lipophilicity, and they probably inhibit central beta adrenergic receptors, 5HT1A and 5HT2 receptors, both of which are thought to decrease alertness, dampen noradrenaline wake-up effect, inhibition of dream suppression and affect visual processing.[6]

While previous propranolol use without such symptoms in the first case suggests a dose or time-dependent effect, the role of co-administered medications (e.g., sodium valproate in the second case) must be considered. Sodium valproate’s CNS effects could have contributed synergistically to the symptoms experienced.

Management and outcomes

Both patients continued propranolol therapy due to its efficacy in migraine management. Counselling was provided about the possible CNS side effects and the importance of monitoring symptom progression. Alternative therapeutic strategies or dose adjustments were considered but not implemented at the time of reporting.

CONCLUSION

These clinical cases highlight rare CNS adverse effects of propranolol, including vivid dreams and oscillopsia, which clinicians should remain aware of, especially in patients requiring long-term beta-blocker therapy for various conditions. Awareness and timely recognition of these adverse effects can guide appropriate patient counselling, reassurance and therapeutic adjustments.

Acknowledgements:

The authors thank the patients for providing consent for the publication of these cases.

Ethical approval:

Institutional Review Board approval is not required.

Declaration of patient consent:

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Conflicts of interest:

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation:

The authors confirm that they have used artificial intelligence (AI)-assisted technology for assisting in grammar correction and language refinement, no data generation or analysis was performed.

Financial support and sponsorship: Nil.

References

  1. . Propranolol: A 50-year historical perspective. Ann Indian Acad Neurol. 2019;22:21-6.
    [CrossRef] [PubMed] [Google Scholar]
  2. , . Medications for migraine prophylaxis. Am Fam Physician. 2006;73:72-8.
    [Google Scholar]
  3. . Central nervous system side-effects with hydrophilic and lipophilic β-blockers. Eur J Clin Pharmacol. 1985;28(Suppl 1):73-6.
    [CrossRef] [PubMed] [Google Scholar]
  4. . Pharmacological, physiological, and familial factors in propranolol-induced visions. Neurol Clin Pract. 2019;10:e25-6.
    [CrossRef] [Google Scholar]
  5. , , , . The man who saw things on carvedilol. Tokai J Exp Clin Med. 2019;44:29-30.
    [Google Scholar]
  6. . CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985;28(Suppl):55-63.
    [CrossRef] [PubMed] [Google Scholar]
Show Sections

Indian Journal of Physiology and Pharmacology

Copyright Form


Title of the Manuscript: ________________________________________


I/We certify that I/we have participated sufficiently in the intellectual content, conception, and design of this work, or the analysis and interpretation of the data (when applicable), as well as the writing of the manuscript, to take public responsibility for it. I/We agree to have my/our name(s) listed as contributors and confirm that the manuscript represents valid work.

Each author confirms they meet the criteria for authorship as established by the ICMJE. Neither this manuscript nor one with substantially similar content under my/our authorship has been published or is being considered for publication elsewhere, except as described in the covering letter.

I/We certify that all data collected during the study is presented in this manuscript and that no data from the study has been or will be published separately. I/We agree to provide, upon request by the editors, any data/information on which the manuscript is based for examination by the editors or their assignees.

I/We have disclosed all financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this manuscript in the cover letter. Sources of outside support for the project are also disclosed in the cover letter.

In accordance with open access principles, I/we grant the Journal the exclusive right to publish and distribute this work under the Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA) license. This license permits others to distribute, transform, adapt, and build upon the material in any medium or format for non-commercial purposes, provided appropriate credit is given to the creator(s). Any adaptations must be shared under the same license terms. The key elements of the CC BY-NC-SA license are:

  • BY: Credit must be given to the original creator(s).
  • NC: Only non-commercial uses of the work are permitted.
  • SA: Adaptations must be shared under the same license terms.

I/We retain academic rights to the material, and the Journal is authorized to:

  1. Grant permission to republish the article in whole or in part, with or without fee.
  2. Produce preprints or reprints and translate the work into other languages for sale or free distribution.
  3. Republish the work in a collection of articles in any mechanical or electronic format.

I/We give the rights to the corresponding author to make necessary changes as requested by the Journal, handle all correspondence on our behalf, and act as the guarantor for the manuscript.

All individuals who have made substantial contributions to the work but do not meet the criteria for authorship are named in the Acknowledgment section with their written permission. If no acknowledgment is provided, it signifies that no substantial contributions were made by non-authors.


Name of the author(s) Signature Date signed Corresponding author?
Yes/No
Yes/No
Yes/No